Colorectal Cancer Alliance announces funding recipients for colon and rectal cancer research needs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Colorectal Cancer Alliance is providing a total of $625,000 in grants to four researchers, including one advancing personalized treatment options for rectal cancer patients and three seeking to understand the root cause of rising colorectal cancer rates in patients under age 50.

Grant recipients include:

  • J. Joshua Smith of Memorial Sloan Kettering Cancer Center who will build on his previous research using patient-specific rectal cancer organoids to grow human-specific rectal cancer models in mice as a platform for developing personalized treatments.

  • Robin B. Mendelson of Memorial Sloan Kettering Cancer Center who will describe the gut microbiome of patients under age of 50, comparing them to the microbiomes of older people with colorectal cancer and the microbiomes of younger healthy people.

  • Joshua Meyer of Fox Chase Cancer Center who will describe the genetic and genomic features of colorectal cancer patients young and old, and thoroughly characterize the biology of young-onset colorectal in patients under 50 years old.

  • Rosa Maria Munoz Xicola of the Yale School of Medicine will provide essential knowledge on how the APC-negative subset of colorectal cancers develop, which is crucial in the development of effective early detection tests and treatments. Xicola will also investigate whether the APC-negative subset disproportionately affects African Americans and young people.

The Colorectal Cancer Alliance is now accepting applications for its prevention research grants. The application deadline is 11:59 p.m., Monday, March 18, 2019.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login